Neurotech
Deep brain stimulation: the neurotech that already works
Hundreds of thousands of people already have electrodes implanted in their brains, and the field has learned things worth carrying forward.
Discussion of brain implants usually treats them as prospective. In fact deep brain stimulation has been an approved therapy for decades and has been implanted in a very large number of patients.
It is the closest thing the field has to a mature product, and its history is instructive.
What it does
Electrodes are implanted in specific deep brain structures and connected to a pulse generator, usually placed under the collarbone.
The device delivers continuous high-frequency electrical stimulation.
For Parkinson's disease — the largest indication — stimulation of the subthalamic nucleus or globus pallidus substantially reduces tremor, rigidity and the motor fluctuations that develop with long-term medication.
It also has established approval for essential tremor, dystonia and, in some jurisdictions, epilepsy and obsessive-compulsive disorder.
The uncomfortable part
Worth stating clearly because it says something about the field.
The precise mechanism is not settled.
Early explanations suggested stimulation simply inhibited the target, mimicking a lesion. Later work indicated a more complex effect on network activity — disrupting pathological oscillatory patterns rather than silencing a structure.
The therapy works, reliably and reproducibly, and the theory has been catching up for thirty years.
This is a useful corrective to the assumption that neurotechnology requires complete understanding before it can be useful.
What the field has learned
Chronic implants can last. Leads remain functional for many years. This is the strongest available evidence that permanent neural hardware is achievable.
The pulse generator's battery is the limiting component, requiring replacement surgery every few years for non-rechargeable units. Rechargeable devices extend this considerably.
Programming matters enormously. The same hardware in the same target can produce excellent or poor outcomes depending on which contacts are active and at what parameters.
Programming sessions take hours and are repeated over months. This is a substantial and underappreciated clinical burden, and directional leads that steer the stimulation field have made it more complex rather than simpler.
Placement accuracy is critical. Millimetres matter, which is why the surgery uses stereotactic frames, intraoperative imaging and in some centres microelectrode recording to confirm the target.
Patient selection determines outcome more than any technical variable. Careful multidisciplinary assessment is the difference between a transformative result and a disappointing one.
The side effects that matter
Reported and studied over a long period, which is exactly what newer devices lack.
Surgical risks: infection, haemorrhage, hardware erosion, lead migration.
Stimulation-related effects: speech changes, gait disturbance, paraesthesia, and effects on mood.
Neuropsychiatric effects are the most discussed. Changes in impulsivity, mood and, in a minority of cases, reported changes in personality or sense of self have been documented.
Most are manageable by adjusting parameters. The existence of the category is itself important information for anyone contemplating more ambitious interventions.
Closed-loop systems
The current direction of development.
Conventional DBS delivers continuous stimulation regardless of the patient's state.
Adaptive or closed-loop systems sense neural signals — typically oscillatory activity associated with symptoms — and modulate stimulation in response.
The rationale is better symptom control, fewer side effects and longer battery life.
Devices with sensing capability are approved and in clinical use, and the algorithms remain an active research area.
This is the same sense-and-respond architecture that ambitious BCI proposals require, being validated in a much lower-risk setting.
What it tells us about the wider field
Implanted neural devices are feasible and can be maintained over decades.
Regulatory approval is achievable for a device with clear indications and measurable outcomes.
The clinical burden is substantial. Programming, follow-up and battery replacement mean the device is a long-term care relationship rather than a one-off procedure.
Effects on identity are real at some rate and require systematic monitoring rather than being treated as an edge case.
Device abandonment is a genuine risk. Patients with implants from discontinued products have been left with unsupported hardware. Any implanted device needs a plan for what happens if the manufacturer stops.
Every one of those lessons applies directly to the more ambitious devices now entering trials, and the newer field has not always sounded aware of them.
